Loading...

Agenus

Nasdaq:AGEN
Snowflake Description

Limited growth with worrying balance sheet.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
AGEN
Nasdaq
$349M
Market Cap
  1. Home
  2. US
  3. Pharmaceuticals & Biotech
Company description

Agenus Inc., a clinical-stage immuno-oncology company, focuses on the discovery and development of therapies that engage the body's immune system to fight cancer. The last earnings update was 36 days ago. More info.


Add to Portfolio Compare Print
  • Agenus has significant price volatility in the past 3 months.
AGEN Share Price and Events
7 Day Returns
-0.8%
NasdaqCM:AGEN
-5.5%
US Biotechs
-0.1%
US Market
1 Year Returns
-27.8%
NasdaqCM:AGEN
-2.6%
US Biotechs
7.6%
US Market
AGEN Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Agenus (AGEN) -0.8% -7.8% -26.6% -27.8% -37.3% -11.6%
US Biotechs -5.5% -3% -3.2% -2.6% -1.9% 16.6%
US Market -0.1% 3.7% 10.2% 7.6% 38.1% 46.4%
1 Year Return vs Industry and Market
  • AGEN underperformed the Biotechs industry which returned -2.6% over the past year.
  • AGEN underperformed the Market in United States of America which returned 7.6% over the past year.
Price Volatility
AGEN
Industry
5yr Volatility vs Market
Related Companies

AGEN Value

 Is Agenus undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.

In this section, we usually try to help investors determine whether Agenus is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Agenus has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis. You can see them here.

Show me the analysis anyway

INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Agenus. This is due to cash flow or dividend data being unavailable. The share price is $2.6.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Agenus's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Agenus's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
NasdaqCM:AGEN PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in USD $-1.44
NasdaqCM:AGEN Share Price ** NasdaqCM (2019-04-23) in USD $2.6
United States of America Biotechs Industry PE Ratio Median Figure of 35 Publicly-Listed Biotechs Companies 18.73x
United States of America Market PE Ratio Median Figure of 3,080 Publicly-Listed Companies 18.03x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Agenus.

NasdaqCM:AGEN PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqCM:AGEN Share Price ÷ EPS (both in USD)

= 2.6 ÷ -1.44

-1.8x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Agenus is loss making, we can't compare its value to the US Biotechs industry average.
  • Agenus is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does Agenus's expected growth come at a high price?
Raw Data
NasdaqCM:AGEN PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -1.8x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 3 Analysts
7.8%per year
United States of America Biotechs Industry PEG Ratio Median Figure of 28 Publicly-Listed Biotechs Companies 1.76x
United States of America Market PEG Ratio Median Figure of 2,109 Publicly-Listed Companies 1.55x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Agenus, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Agenus's assets?
Raw Data
NasdaqCM:AGEN PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in USD $-1.44
NasdaqCM:AGEN Share Price * NasdaqCM (2019-04-23) in USD $2.6
United States of America Biotechs Industry PB Ratio Median Figure of 416 Publicly-Listed Biotechs Companies 3.27x
United States of America Market PB Ratio Median Figure of 5,185 Publicly-Listed Companies 1.92x
NasdaqCM:AGEN PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqCM:AGEN Share Price ÷ Book Value per Share (both in USD)

= 2.6 ÷ -1.44

-1.81x

* Primary Listing of Agenus.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Agenus has negative assets, we can't compare the value of its assets to the US Biotechs industry average.

Next steps:

  1. Take a look at our analysis of AGEN’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  2. When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don’t know where to start, we recommend reading through Agenus's regulatory filings and announcements.
  3. Show me more potentially undervalued companies in the Biotechs industry
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Value checks
We assess Agenus's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Agenus has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

AGEN Future Performance

 How is Agenus expected to perform in the next 1 to 3 years based on estimates from 3 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
7.8%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Agenus expected to grow at an attractive rate?
  • Unable to compare Agenus's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
  • Unable to compare Agenus's earnings growth to the United States of America market average as it is expected to be loss making during the next 1-3 years.
  • Agenus's revenue growth is expected to exceed the United States of America market average.
Annual Growth Rates Comparison
Raw Data
NasdaqCM:AGEN Future Growth Rates Data Sources
Data Point Source Value (per year)
NasdaqCM:AGEN Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 3 Analysts 7.8%
NasdaqCM:AGEN Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 3 Analysts 45.7%
United States of America Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 18.5%
United States of America Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 15.1%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 13.5%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.1%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
NasdaqCM:AGEN Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
NasdaqCM:AGEN Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 175 -93 3
2022-12-31 91 -165 3
2021-12-31 37 -193 3
2020-12-31 9 -200 2
2019-12-31 22 -180 3
NasdaqCM:AGEN Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-12-31 37 -131 -160
2018-09-30 39 -121 -147
2018-06-30 29 -123 -151
2018-03-31 18 -120 -158
2017-12-31 43 -94 -121
2017-09-30 40 -84 -112
2017-06-30 41 -82 -116
2017-03-31 44 -73 -113
2016-12-31 23 -80 -127
2016-09-30 25 -83 -117
2016-06-30 27 -78 -89
2016-03-31 27 -72 -101

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Agenus is not considered high growth as it is expected to be loss making for the next 1-3 years.
  • Agenus's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
NasdaqCM:AGEN Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below

All data from Agenus Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqCM:AGEN Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 -0.55 -0.12 -1.26 3.00
2022-12-31 -1.15 -0.93 -1.36 2.00
2021-12-31 -1.48 -1.45 -1.51 2.00
2020-12-31 -1.48 -1.40 -1.56 2.00
2019-12-31 -1.26 -1.11 -1.43 3.00
NasdaqCM:AGEN Past Financials Data
Date (Data in USD Millions) EPS *
2018-12-31 -1.44
2018-09-30 -1.39
2018-06-30 -1.48
2018-03-31 -1.57
2017-12-31 -1.23
2017-09-30 -1.18
2017-06-30 -1.26
2017-03-31 -1.27
2016-12-31 -1.46
2016-09-30 -1.35
2016-06-30 -1.04
2016-03-31 -1.22

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Agenus will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Agenus's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Agenus has a total score of 2/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

AGEN Past Performance

  How has Agenus performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Agenus's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Agenus does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Agenus's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Agenus's 1-year growth to the US Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Agenus's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Agenus Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqCM:AGEN Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 36.78 -159.90 37.34
2018-09-30 38.69 -147.18 37.40
2018-06-30 29.24 -150.89 36.25
2018-03-31 17.56 -157.94 34.90
2017-12-31 42.88 -120.90 33.74
2017-09-30 40.10 -111.99 32.63
2017-06-30 41.19 -115.92 32.68
2017-03-31 43.57 -112.52 31.66
2016-12-31 22.57 -127.20 33.13
2016-09-30 24.64 -116.68 32.92
2016-06-30 27.04 -89.03 31.22
2016-03-31 26.82 -101.12 32.11
2015-12-31 24.82 -88.08 28.37
2015-09-30 18.80 -98.46 24.95
2015-06-30 13.51 -93.44 23.46
2015-03-31 10.21 -61.07 21.57
2014-12-31 6.98 -42.69 21.25
2014-09-30 5.75 -22.49 19.58
2014-06-30 4.92 -21.70 18.24
2014-03-31 2.66 -24.80 16.76
2013-12-31 3.05 -33.23 14.48
2013-09-30 3.74 -33.04 13.76
2013-06-30 3.88 -31.60 12.77
2013-03-31 3.70 -27.53 11.48
2012-12-31 15.96 -12.12 11.47
2012-09-30 15.51 -12.70 11.53
2012-06-30 15.30 -12.50 11.51 -5.64

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Agenus has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) due to its liabilities exceeding its assets.
  • It is difficult to establish if Agenus has efficiently used its assets last year compared to the US Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Agenus improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Agenus's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Agenus has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

AGEN Health

 How is Agenus's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Agenus's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Agenus is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Agenus's long term commitments exceed its cash and other short term assets.
Balance sheet
This treemap shows a more detailed breakdown of Agenus's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Agenus has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Agenus Company Filings, last reported 3 months ago.

NasdaqCM:AGEN Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 -134.67 13.83 53.05
2018-09-30 -131.39 13.74 46.17
2018-06-30 -113.09 13.74 43.16
2018-03-31 -113.23 13.47 52.35
2017-12-31 -75.82 163.02 60.19
2017-09-30 -51.59 143.94 70.05
2017-06-30 -17.48 139.14 96.77
2017-03-31 8.90 134.83 123.82
2016-12-31 -39.13 130.69 76.44
2016-09-30 -21.04 126.41 95.40
2016-06-30 16.88 122.27 123.29
2016-03-31 44.45 118.31 148.23
2015-12-31 70.73 114.47 171.67
2015-09-30 76.98 110.70 199.13
2015-06-30 87.19 11.43 139.64
2015-03-31 46.26 11.50 79.30
2014-12-31 23.02 6.03 40.22
2014-09-30 48.87 6.72 52.91
2014-06-30 57.63 7.43 62.82
2014-03-31 63.29 9.36 73.49
2013-12-31 -4.48 8.87 27.35
2013-09-30 -2.88 9.33 30.20
2013-06-30 -17.26 9.23 13.44
2013-03-31 -22.68 36.35 17.21
2012-12-31 -17.60 35.92 21.47
2012-09-30 -13.16 35.51 24.76
2012-06-30 -11.36 35.20 25.46
  • Agenus has negative shareholder equity (liabilities exceed assets), this is a more serious situation compared with a high debt level.
  • Irrelevant to check if Agenus's debt level has increased considering it has negative shareholder equity.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Agenus has less than a year of cash runway based on current free cash flow.
  • Agenus has less than a year of cash runway if free cash flow continues to grow at historical rates of 23.1% each year.
X
Financial health checks
We assess Agenus's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Agenus has a total score of 1/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

AGEN Dividends

 What is Agenus's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Agenus dividends.
If you bought $2,000 of Agenus shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Agenus's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Agenus's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
NasdaqCM:AGEN Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below
Global Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 20 Stocks 2.5%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 2008 Stocks 2.4%
United States of America Minimum Threshold Dividend Yield 10th Percentile 0.8%
United States of America Bottom 25% Dividend Yield 25th Percentile 1.4%
United States of America Top 25% Dividend Yield 75th Percentile 3.6%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

NasdaqCM:AGEN Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2019-12-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Agenus has not reported any payouts.
  • Unable to verify if Agenus's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Agenus's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Agenus has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Agenus's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Agenus afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Agenus has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

AGEN Management

 What is the CEO of Agenus's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Garo Armen
COMPENSATION $3,769,681
AGE 65
TENURE AS CEO 25.3 years
CEO Bio

Dr. Garo H. Armen, Ph.D., founded Agenus Inc. in 1994 and has been its Chief Executive Officer since 1994. Dr. Armen serves as an Executive Chairman of Agenus Inc. He has been an Executive Director of Agenus Inc. since 1999. He served as the President of Antigenics since January 2002. Prior to Agenus Inc., he established Armen Partners, a money management firm specializing in biotechnology and pharmaceutical companies and was the architect of the widely publicized creation of the Immunex Lederle oncology business in 1993. Since 1990, Dr. Armen served as the Managing General Partner of Armen Partners, LP, an investment partnership specializing in public and private healthcare and biotechnology investments. He previously served as Senior Vice President of Research for Dean Witter Reynolds, Research Division, focusing on the chemical and pharmaceutical industries and with E.F. Hutton & Company as first Vice President of research. He serves as the Chairman of Protagenic Therapeutics Inc. and Elan Drug Delivery Inc. Dr. Armen served as Chairman of Elan Corporation, plc from July 2002 to January 2005. He has been a Director of Philips Solid-State Lighting Solutions, Inc. (formerly, Color Kinetics Inc.) since 1998. He serves as a Director of ScrollMotion, Inc. He served as a Non Executive Director of Elan Corporation, plc from February 1994 to May 2006. He has served as an Associate Professor at the Merchant Marine Academy and as a Research Associate at the Brookhaven National Laboratory. In 2002, he founded the Children of Armenia Fund and serves as its Chairman. He received the Ellis Island Medal of Honor in 2004 for his humanitarian efforts and received the Sabin Humanitarian Award from the Sabin Vaccine Institute in 2006 for his achievements in biotechnology and progressing medical research. He was also the Ernst & Young 2002 New York City Biotechnology Entrepreneur of the Year and received a Wings of Hope Award in 2005 from The Melanoma Research Foundation for his ongoing commitment to the melanoma community. Dr. Armen received his Ph.D. in Physical Organic Chemistry from the City University of New York in 1979.

CEO Compensation
  • Garo's compensation has increased whilst company is loss making.
  • Garo's remuneration is higher than average for companies of similar size in United States of America.
Management Team Tenure

Average tenure and age of the Agenus management team in years:

1.5
Average Tenure
59
Average Age
  • The average tenure for the Agenus management team is less than 2 years, this suggests a new team.
Management Team

Garo Armen

TITLE
Founder
COMPENSATION
$4M
AGE
65
TENURE
25.3 yrs

Christine Klaskin

TITLE
Principal Accounting Officer & VP of Finance
COMPENSATION
$497K
AGE
52
TENURE
12.5 yrs

Alex Duncan

TITLE
CTO & Head of Research
COMPENSATION
$858K
AGE
56
TENURE
3.3 yrs

Bob Stein

TITLE
Senior R&D Advisor
COMPENSATION
$1M
AGE
67
TENURE
2 yrs

Chris Cortis

TITLE
Chief Strategy Officer & Head of Finance
AGE
50
TENURE
0.8 yrs

Jennifer Buell

TITLE
Chief Operating Officer
TENURE
0.4 yrs

Evan Kearns

TITLE
VP, General Counsel & Secretary
TENURE
0.8 yrs

Ozer Baysal

TITLE
Chief Commercial Officer & Head of HR
COMPENSATION
$462K
AGE
62
TENURE
1.8 yrs

John Castle

TITLE
Head of Translational Medicine & Bioinformatics
TENURE
1.3 yrs

Paulo Moreira

TITLE
Global Head of Clinical Operations
TENURE
0.1 yrs
Board of Directors Tenure

Average tenure and age of the Agenus board of directors in years:

10.3
Average Tenure
60
Average Age
  • The average tenure for the Agenus board of directors is over 10 years, this suggests they are a seasoned and experienced board.
Board of Directors

Garo Armen

TITLE
Founder
COMPENSATION
$4M
AGE
65

Wadih Jordan

TITLE
Independent Director
COMPENSATION
$212K
AGE
83
TENURE
16.1 yrs

Brian Corvese

TITLE
Independent Director
COMPENSATION
$317K
AGE
60
TENURE
12.1 yrs

Tim Wright

TITLE
Lead Director
COMPENSATION
$306K
AGE
60
TENURE
10.3 yrs

Ulf Wiinberg

TITLE
Director
COMPENSATION
$242K
AGE
60
TENURE
2.9 yrs

Allison Jeynes-Ellis

TITLE
Director
TENURE
0.4 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
X
Management checks
We assess Agenus's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Agenus has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

AGEN News

Simply Wall St News

What Should We Expect From Agenus Inc.'s (NASDAQ:AGEN) Earnings In The Next Couple Of Years?

The latest earnings update Agenus Inc. … (NASDAQ:AGEN) released in December 2018 … company earnings became less negative compared to the previous year's level

Simply Wall St -

Agenus Inc (NASDAQ:AGEN): Are Analysts Right About The Drop In Earnings?

Based on Agenus Inc's (NASDAQ:AGEN) earnings update in March 2018,. … with profits predicted to drop by -10.22% next year … compared to its 5-year track record of the average earnings growth rate of -33.80%, this is still an improvement.

Simply Wall St -

Does Agenus Inc's (NASDAQ:AGEN) 12.7% EPS Growth Reflect The Long-Term Trend?

Today I will assess AGEN's recent performance announced on 30 September 2017 and compare these figures to its historical trend and industry movements. … See our latest analysis for Agenus How Did AGEN's Recent Performance Stack Up Against Its Past? … I look at the ‘latest twelve-month’ data, which annualizes the latest 6-month earnings release, or some times, the latest annual report is already the most recent financial data.

Simply Wall St -

Does Agenus Inc's (AGEN) CEO Pay Compared Well With Peers?

NasdaqCM:AGEN Past Future Earnings Nov 18th 17 Is AGEN's CEO overpaid relative to the market? … Typically I'd use market cap and profit as factors determining performance, however, AGEN's negative earnings lower the effectiveness of this method. … Although remuneration can be a useful gauge of whether Armen's incentives are well-aligned with AGEN's shareholders, it is certainly not sufficient to base your investment decision solely on this factor.

Simply Wall St -

AGEN Company Info

Description

Agenus Inc., a clinical-stage immuno-oncology company, focuses on the discovery and development of therapies that engage the body's immune system to fight cancer. The company offers Retrocyte Display, an antibody discovery platform for the identification of fully-human and humanized monoclonal antibodies; SECANT yeast display, an antibody discovery platform used for the generation of novel monoclonal antibodies; and phage display technologies. It is also developing checkpoint modulating antibody candidates targeting GITR, OX40, TIM-3, LAG-3, and others. In addition, the company develops vaccine programs, including Prophage vaccine candidate; AutoSynVax, a synthetic neoantigen; and PhosPhoSynVax, a vaccine candidate designed to induce immunity against a class of tumor specific neoepitopes. Further, it develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. Additionally, the company engages in the development of CTLA-4 and PD-1 antagonists; and anti-CTLA-4, CD137, and TIGIT antibodies, as well as various multi-specific antibodies that are under various stages of development. Agenus Inc. has collaboration agreements with Incyte Corporation, Merck Sharpe & Dohme, and Recepta Biopharma SA.; and collaboration with Gilead Sciences, Inc. to develop immuno-oncology therapies. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.

Details
Name: Agenus Inc.
AGEN
Exchange: NasdaqCM
Founded: 1994
$348,933,972
134,205,374
Website: http://agenusbio.com
Address: Agenus Inc.
3 Forbes Road,
Lexington,
Massachusetts, 02421,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqCM AGEN Common Stock Nasdaq Capital Market US USD 04. Feb 2000
DB AJ81 Common Stock Deutsche Boerse AG DE EUR 04. Feb 2000
Number of employees
Current staff
Staff numbers
294
Agenus employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/23 23:32
End of day share price update: 2019/04/23 00:00
Last estimates confirmation: 2019/04/22
Last earnings filing: 2019/03/18
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.